Laboratory data

Published on 02/03/2015 by admin

Filed under Basic Science

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1647 times

6 Laboratory data

This chapter will consider the common biochemical and haematological tests that are of clinical and diagnostic importance. For convenience, each individual test will be dealt with under a separate heading and a brief review of the physiology and pathophysiology will be given where appropriate to explain the basis of biochemical and haematological disorders.

It is usual for a reference range to be quoted for each individual test (see Tables 6.1 and 6.4). This range is based on data obtained from a sample of the general population which is assumed to be disease-free. Many test values have a normal distribution and the reference values are taken as the mean ± 2 standard deviations (SD). This includes 95% of the population. The ‘normal’ range must always be used with caution since it takes little account of an individual’s age, sex, weight, height, muscle mass or disease state, many of which variables can influence the value obtained. Although reference ranges are valuable guides, they must not be used as sole indicators of health and disease. A series of values rather than a simple test value may be required in order to ensure clinical relevance and to eliminate erroneous values caused, for example, by spoiled specimens or interference from diagnostic or therapeutic procedures. Furthermore, a disturbance of one parameter often cannot be considered in isolation without looking at the pattern of other tests within the group.

Table 6.1 Biochemical data: typical normal adult reference values measured in serum

Laboratory test Reference range
Urea and electrolytes
Sodium 135–145 mmol/L
Potassium 3.4–5.0 mmol/L
Calcium (total) 2.12–2.60 mmol/L
Calcium (ionised) 1.19–1.37 mmol/L
Phosphate 0.80–1.44 mmol/L
Magnesium 0.7–1.00 mmol/L
Creatinine 75–155 μmol/L
Urea3.1–7.9 mmol/L
Estimated glomerular filtration rate (eGFR) ≥ 90 ml/min/1.73m2
Glucose
Fasting 3.3–6.0 mmol/L
Non-fasting <11.1 mmol/L
Glycated haemoglobin Non-diabetic subjects <43 mmol/mol
Inadequate control >58 mmol/mol
Liver function tests
Albumin 34–50 g/L
Bilirubin (total) <19 μmol/L
Enzymes
Alanine transaminase <45 U/L
Aspartate transaminase <35 U/L
Alkaline phosphatase 35–120 U/L
γ-Glutamyl transpeptidase <70 U/L
Ammonia
Men 15–50 μmol/L
Female 10–40 μmol/L
Amylase <100 U/L
Cardiac markers
Troponin I (99th percentile of upper reference limit) 0.04 μcg/L
Other tests
C-reactive protein (CRP) 0–5 mg/L
Osmolality 282–295 mOsmol/kg
Uric acid 0.15–0.47 mmol/L
Parathyroid hormone (adult with normal calcium) 10–65 ng/L
25-Hydroxyvitamin D >75 nmol/L (optimal)
>50 nmol/L (sufficient)
30–50 nmol/L (insufficient)
12–30 nmol/L (deficient)
<12 nmol/L (severely deficient)

Table 6.4 Haematology data: typical normal adult reference values

Haemoglobin 11.5–16.5 g/dL
Red blood cell (RBC) count 3.8–4.8 × 1012/L
Reticulocyte count 50–100 × 109/L
Packed cell volume (PCV) 0.36–0.46 L/L
Mean cell volume (MCV) 83–101 fL
Mean cell haemoglobin (MCH) 27–34 pg
Mean cell haemoglobin concentration (MCHC) 31.5–34.5 g/dL
White cell count (WBC) 4.0–11.0 × 109/L
Differential white cell count:
Neutrophils (30–75%) 2.0–7.0 × 109/L
Lymphocytes (5–15%) 1.5–4.0 × 109/L
Monocytes (2–10%) 0.2–0.8 ×109/L
Basophils (<1%) <0.1 × 109/L
Eosinophils (1–6%) 0.04–0.4 × 109/L
Platelets 150–450 × 109/L
Erythrocyte sedimentation rate (ESR) 1–35 mm/h
D-dimers 0–230 ng/mL
Ferritin 15–300 μcg/L
Total iron binding capacity (TIBC) 47–70 μmol/L
Serum B12 170–700 ng/L
Red cell folate 160–600 μcg/l
Iron 11–29 μmol/L
Transferrin 1.7–3.4 g/L

Further specific information on the clinical and therapeutic relevance of each test may be obtained by referral to the relevant chapter in this book.

Biochemical data

The homeostasis of various elements, water and acid–base balance are closely linked, both physiologically and clinically. Standard biochemical screening includes several measurements which provide a picture of fluid and electrolyte balance and renal function. These are commonly referred to colloquially as ‘Us and Es’ (urea and electrolytes) and the major tests are described below.

Sodium and water balance

Sodium and water metabolism are closely interrelated both physiologically and clinically, and play a major role in determining the osmolality of serum.

Water constitutes approximately 60% of body weight in men and 55% in women (women have a greater proportion of fat tissue which contains little water). Approximately two-thirds of body water is found in the intracellular fluid (ICF) and one-third in the extracellular fluid (ECF). Of the ECF 75% is found within interstitial fluid and 25% within serum (Fig. 6.1). Total body water is regulated by the renal action of antidiuretic hormone (ADH), the renin angiotensin–aldosterone system, noradrenaline/norepinephrine and by thirst which is stimulated by rising plasma osmolality.

In general, water permeates freely between the ICF and ECF. Cell walls function as semipermeable membranes, with water movement from one compartment to the other being controlled by osmotic pressure: water moves into the compartment with the higher osmotic concentration. The osmotic content of the two compartments is generally the same, that is, they are isotonic, which ensures normal cell membrane integrity and cellular processes. However, the kidneys are an exception to the rule.

The osmolality of the ECF is largely determined by sodium and its associated anions, chloride and bicarbonate. Glucose and urea have a lesser, but nevertheless important, role in determining ECF osmolality. Protein, especially albumin, makes only a small (0.5%) contribution to the osmolality of the ECF but is a major factor in determining water distribution between the two compartments. The contribution of proteins to the osmotic pressure of serum is known as the colloid osmotic pressure or oncotic pressure.

The major contributor to the osmolality of the ICF is potassium.

The amount of water taken in and lost by the body depends on intake, diet, activity and the environment. Over time the intake of water is normally equal to that lost (Table 6.2). The minimum daily intake necessary to maintain this balance is approximately 1100 mL. Of this, 500 mL is required for normal excretion of waste products in urine, whilst the remaining volume is lost via the skin in sweat, via the lungs in expired air, and in faeces. The kidneys regulate water balance, water being filtered, then reabsorbed in variable amounts depending primarily on the level of ADH.

Hypernatraemia

The signs and symptoms of hypernatraemia include muscle weakness and confusion.

Drug-induced hypernatraemia is often the result of a nephrogenic diabetes insipidus-like syndrome whereby the renal tubules are unresponsive to ADH. The affected patient presents with polyuria, polydipsia or dehydration.

Hypernatraemia can be caused by a number of other drugs (Box 6.1) and by a variety of mechanisms; for example, hypernatraemia secondary to sodium retention is known to occur with corticosteroids whilst the administration of sodium-containing drugs parenterally in high doses also has the potential to cause hypernatraemia.

Potassium

The total amount of potassium in the body, like sodium, is 3000 mmol. About 10% of the body potassium is bound in red blood cells (RBCs), bone and brain tissue and is not exchangeable. The remaining 90% of total body potassium is free and exchangeable with the vast majority having an intracellular location, being pumped in and out by Na/K-ATPase pumps. This is controlled by mechanisms aimed at ensuring stable intracellular to extracellular ratios, and hence correct muscular and neuronal excitability. Only 2% of the exchangeable total body potassium is in the ECF, the compartment from where the serum concentration is sampled and measured. Consequently, the measurement of serum potassium is not an accurate index of total body potassium, but together with the clinical status of a patient it permits a sound practical assessment of potassium homeostasis.

The serum potassium concentration is controlled mainly by the kidney with the gastro-intestinal tract normally having a minor role. The potassium filtered in the kidney is almost completely reabsorbed in the proximal tubule. Potassium secretion is largely a passive process in response to the need to maintain membrane potential neutrality associated with active reabsorption of sodium in the distal convoluted tubule and collecting duct. The extent of potassium secretion is determined by a number of factors including:

As described above, both potassium and hydrogen can neutralise the membrane potential generated by active sodium reabsorption and consequently there is a close relationship between potassium and hydrogen ion homeostasis. In acidosis, hydrogen ions are normally secreted in preference to potassium and potassium moves out of cells, that is, hyperkalaemia is often associated with acidosis, except in renal tubular acidosis. In alkalosis, fewer hydrogen ions will be present and potassium moves into cells and potassium is excreted, that is, hypokalaemia is often associated with alkalosis.

The normal daily dietary intake of potassium is of the order of 60–200 mmol, which is more than adequate to replace that lost from the body. It is unusual for a deficiency in intake to account for hypokalaemia. A transcellular movement of potassium into cells, loss from the gut or excretion in the urine are the main causes of hypokalaemia.

Hypokalaemia

Hyperkalaemia

Hyperkalaemia may arise from excessive intake, decreased elimination or shift of potassium from cells to the ECF. It is rare for excessive oral intake to be the sole cause of hyperkalaemia. The inappropriate use of parenteral infusions containing potassium is probably the most common iatrogenic cause of excessive intake. Hyperkalaemia is a common problem in patients with renal failure due to their inability to excrete a potassium load.

The combined use of potassium-sparing diuretics such as amiloride, triamterene or spironolactone with an angiotensin converting enzyme (ACE) inhibitor, which will lower aldosterone, is a recognised cause of hyperkalaemia, particularly in the elderly. Mineralocorticoid deficiency states such as Addison’s disease where there is a deficiency of aldosterone also decrease renal potassium loss and contribute to hyperkalaemia. Those at risk of hyperkalaemia should be warned not to take dietary salt (NaCl) substitutes in the form of KCl.

The majority of body potassium is intracellular. Severe tissue damage, catabolic states or impairment of the energy-dependent sodium pump, caused by hypoxia or diabetic ketoacidosis, may result in apparent hyperkalaemia due to potassium moving out of and sodium moving into cells. If serum potassium rises, insulin release is stimulated which, through increasing activity in Na/K-ATPase pumps, causes potassium to move into cells. Box 6.4 gives examples of some drugs known to cause hyperkalaemia.

Haemolysis during sampling or a delay in separating cells from serum will result in potassium escaping from blood cells into serum and causing an artefactual hyperkalaemia.

Calcium

The body of an average man contains about 1 kg of calcium and 99% of this is bound within bone. Calcium is present in serum bound mainly to the albumin component of protein (46%), complexed with citrate and phosphate (7%), and as free ions (47%). Only the free ions of calcium are physiologically active. Calcium metabolism is regulated by 1,25-dihydroxycholecalciferol (vitamin D) which, when serum calcium is low, is secreted to promote gastro-intestinal absorption of calcium, and by parathyroid hormone (PTH) which is inhibited by increased serum concentrations of calcium ions. PTH is secreted in response to low calcium concentrations and increases serum calcium by actions on osteoclasts, kidney and gut.

The serum calcium level is often determined by measuring total calcium, that is, that which is free and bound but the measurement of free or ionised calcium offers advantages in some situations.

In alkalosis, hydrogen ions dissociate from albumin, and calcium binding to albumin increases, together with an increase in complex formation. If the concentration of ionised calcium falls sufficiently, clinical symptoms of hypocalcaemia may occur despite the total serum calcium concentration being unchanged. The reverse effect, that is, increased ionised calcium, occurs in acidosis.

Changes in serum albumin also affect the total serum calcium concentration independently of the ionised concentration. A variety of equations are available to estimate the calcium concentration and many laboratories report total and adjusted calcium routinely. A commonly used formula is shown in Fig. 6.2. Caution must be taken when using such a formula in the presence of disturbed blood hydrogen ion concentrations.

Hypocalcaemia

Hypocalcaemia can be caused by a variety of disorders including severe malnutrition, hypoalbuminaemia, hypoparathyroidism, pancreatitis and those that cause vitamin D deficiency, for example, malabsorption, reduced exposure to sunlight, liver disease and renal disease. In alkalaemia, which may occur when a patient is hyperventilating, there is an increase in protein binding of calcium, which can result in a fall in serum levels of ionised calcium, manifesting itself as paraesthesiae or tetany.

Drugs that have been implicated as causing hypocalcaemia include bisphosphonates which suppress formation and function of osteoclasts, phenytoin, phenobarbital, aminoglycosides, phosphate enemas, calcitonin, cisplatin, mithramycin and furosemide.

Biochemical measurements of serum calcium, phosphate and alkaline phosphatase can be normal in some patients with vitamin D deficiency and osteomalacia. The recent development of non-radioactive automated assays for serum PTH and 25-hydroxy vitamin D (25-OHD) has made measurement of these two hormones possible in many laboratories. There is a lack of consensus regarding a specific level of 25-OHD that is indicative of vitamin D deficiency, but this has usually been established by assessing the point at which serum PTH starts to rise. This, together with methodological and technical issues, prevents direct comparison of values across laboratories. Clinical decision limits for PTH and 25-OHD are laboratory specific and must be interpreted within the clinical context of each patient.

Magnesium

Magnesium is an essential cation, found primarily in bone, muscle and soft tissue. About 1% of the total body content is in the ECF. As an important cofactor for numerous enzymes and ATP, it is critical in energy requiring metabolic processes, protein synthesis, membrane integrity, nervous tissue conduction, neuromuscular excitability, muscle contraction, hormone secretion and in intermediary metabolism. Serum magnesium levels are usually maintained within a tight range (0.7–1.0 mmol/L). Although a serum concentration of less than this usually indicates some level of magnesium depletion, serum levels may be normal in spite of low intracellular magnesium due to magnesium depletion. Hypocalcaemia is a prominent manifestation of moderate to severe magnesium deficiency in humans.

Hypomagnesaemia is frequently seen in critically ill patients. Causes include excessive gastro-intestinal losses, renal losses, surgery, trauma, infection, malnutrition and sepsis. The drugs most likely to induce significant hypomagnesaemia are cisplatin, amphotericin B and ciclosporin, but it is also a potential complication of treatment with amikacin, gentamicin, laxatives, pentamidine, tobramycin, tacrolimus and carboplatin. A hypomagnesaemic effect of furosemide and hydrochlorothiazide is questionable and routine monitoring and treatment are not required. Use of digoxin has been associated with hypomagnesaemia, possibly by enhancing magnesium excretion, which may predispose to digoxin toxicity, for example, dysrhythmias.

Where treatment is indicated, oral supplements are available but because of their slow onset of action and gastro-intestinal intolerance the intravenous route is often preferred and especially in critically ill patients with severe symptomatic hypomagnesaemia.

Hypermagnesaemia is most commonly caused by renal insufficiency and excess iatrogenic magnesium administration.

Creatinine

Serum creatinine concentration is largely determined by its rate of production, rate of renal excretion and volume of distribution. It is frequently used to evaluate renal function.

Creatinine is produced at a fairly constant rate from creatine and creatine phosphate in muscle. Daily production is a function of muscle mass and declines with age from 24 mg/kg/day in a healthy 25-year-old to 9 mg/kg/day in a 95-year-old. Creatinine undergoes complete glomerular filtration with little reabsorption by the renal tubules. Its clearance is, therefore, usually a good indicator of the glomerular filtration rate (GFR). As a general rule, and only at the steady state, if the serum creatinine doubles this equates to a 50% reduction in the GFR and consequently renal function. The serum creatinine level can be transiently elevated following meat ingestion, but less so than urea, or strenuous exercise. Individuals with a high muscle bulk produce more creatinine and, therefore, have a higher serum creatinine level compared to an otherwise identical but less muscular individual.

The value for creatinine clearance is higher than the true GFR due to the active tubular secretion of creatinine. In a patient with a normal GFR, this is of little significance. However, in an individual in whom the GFR is low (<10 mL/min), the tubular secretion may make a significant contribution to creatinine elimination and overestimate the GFR. In this type of patient, the breakdown of creatinine in the gut can also become a significant source of elimination. Some drugs including trimethoprim and cimetidine inhibit creatinine secretion, reducing creatinine clearance and elevating serum creatinine without affecting the GFR.

Bicarbonate and acid–base

Bicarbonate acts as part of the carbonic acid–bicarbonate buffer system, which is important to maintain acid–base balance and thus the pH of the blood. pH homeostasis is accomplished through the interaction of lungs, kidneys and blood buffers. This interaction is best represented by the Henderson–Hasselbalch equation, an equation by which the pH of a buffer solution, blood plasma being one, can be determined (Fig. 6.3).

Plasma bicarbonate is controlled mainly by kidney and blood buffers. The lungs control the PaCO2.

In metabolic acidosis such as that which occurs in renal failure, diabetic ketoacidosis or salicylate poisoning, bicarbonate levels fall. In metabolic alkalosis, the plasma bicarbonate concentration is high. This can occur, for instance, when there is a loss of hydrogen ions from the stomach, as in severe vomiting, or loss through the kidneys, as in mineralocorticoid excess or severe potassium depletion. In the latter situation, an increase in sodium reabsorption in the kidney results in bicarbonate retention and a loss of hydrogen ions. The blood buffer system of carbonic acid/bicarbonate base can act immediately to prevent excessive change in pH. The respiratory system takes a few minutes but the kidneys up to several days to readjust H+ ions concentration.

Liver function tests (LFTs)

Routine LFTs give information mainly about the activity or concentrations of enzymes and compounds in serum rather than quantifying specific hepatic functions and must be interpreted in the context of the patient’s characteristic and the pattern of the abnormalities. Results are useful in confirming or excluding a diagnosis of clinically suspected liver disease, and monitoring its course.

Serum albumin levels and prothrombin time (PT) indicate hepatic protein synthesis; bilirubin is a marker of overall liver function.

Transaminase levels indicate hepatocellular injury and death, while alkaline phosphatase levels estimate the amount of impedance of bile flow.

Albumin

Albumin is quantitatively the most important protein synthesised in the liver, with 10–15 g/day being produced in a healthy man. About 60% is located in the interstitial compartment of the ECF, the remainder in the smaller, but relatively impermeable, serum compartment where it is present at a higher concentration. The concentration in the serum is important in maintaining its volume since it accounts for approximately 80% of serum colloid osmotic pressure. A reduction in serum albumin concentration often results in oedema.

Albumin has an important role in binding, among others, calcium, bilirubin and many drugs. A reduction in serum albumin will increase free levels of agents which are normally bound and adverse effects can result if the ‘free’ entity is not rapidly cleared from the body.

The serum concentration of albumin depends on its rate of synthesis, volume of distribution and rate of catabolism. Synthesis falls in parallel with increasing severity of liver disease or in malnutrition states where there is an inadequate supply of amino acids to maintain albumin production. Synthesis also decreases in response to inflammatory mediators such as interleukin. A low serum albumin concentration will occur when the volume of distribution of albumin increases, as happens, for example, in cirrhosis with ascites, in fluid retention states such as pregnancy or where a shift of albumin from serum to interstitial fluid causes dilutional hypoalbuminaemia after parenteral infusion of excess protein-free fluid. The movement of albumin from serum into interstitial fluid is often associated with increased capillary permeability in post-operative patients or those with septicaemia.

Other causes of hypoalbuminaemia include catabolic states associated with a variety of illnesses and increased loss of albumin, either in urine from damaged kidneys, as occurs in the nephrotic syndrome, or via the skin following burns or a skin disorder such as psoriasis, or from the intestinal wall in a protein-losing enteropathy. The finding of hypoalbuminaemia and no other alteration in liver tests virtually rules out hepatic origin of this abnormality.

Albumin’s serum half-life of approximately 20 days precludes its use as an indicator of acute change in liver function but levels are of prognostic value in chronic disease.

An increase in serum albumin is rare and can be iatrogenic, for example, inappropriate infusion of albumin, or the result of dehydration or shock.

A shift of protein is known to occur physiologically when moving from lying down to the upright position. This can account for an increase in the serum albumin level of up to 10 g/L and can contribute to the variation in serum concentration of highly bound drugs which are therapeutically monitored.

Bilirubin

At the end of their life, RBCs are broken down by the reticuloendothelial system, mainly in the spleen. The haemoglobin molecules, which are subsequently liberated, are split into globin and haem. The globin enters the general protein pool, the iron in haem is reutilised, and the remaining tetrapyrrole ring of haem is degraded to bilirubin. Unconjugated bilirubin, which is water insoluble and fat soluble, is transported to the liver tightly bound to albumin. Unconjugated hyperbilirubinaemia in adults is most commonly the result of haemolysis, or Gilbert’s syndrome due to genetic defects in UDP-glucronyltransferase. It is actively taken up by hepatocytes, conjugated with glucuronic acid and excreted into bile. The conjugated bilirubin is water soluble and secreted rapidly into the gut where it is broken down by bacteria into urobilinogen, a colourless compound, which is subsequently oxidised in the colon to urobilin, a brown pigment excreted in faeces. Some of the urobilinogen is absorbed and most is subsequently re-excreted in bile (enterohepatic circulation). A small amount is absorbed into the systemic circulation and excreted in urine, where it too may be oxidised to urobilin. The presence of increased conjugated bilirubin is usually a sign of liver disease.

The liver produces 300 mg of bilirubin each day. However, because the mature liver can metabolise and excrete up to 3 g daily, serum bilirubin concentrations are not a sensitive test of liver function. As a screening test they rarely do other than confirm the presence or absence of jaundice. In chronic liver disease, however, changes in bilirubin concentrations over time do convey prognostic information.

An elevation of serum bilirubin concentration above 50 μmol/L (i.e. approximately 2.5 times the normal upper limit) will reveal itself as jaundice, seen best in the skin and sclerae. Elevated bilirubin levels can be caused by increased production of bilirubin (e.g. haemolysis, ineffective erythropoiesis), impaired transport into hepatocytes (e.g. interference with bilirubin uptake by drugs such as rifampicin or due to hepatitis), decreased excretion (e.g. with drugs such as rifampicin and methyltestosterone, intrahepatic obstruction due to cirrhosis, tumours, etc.) or a combination of the above factors.

The bilirubin in serum is normally unconjugated, bound to protein, not filtered by the glomeruli and does not normally appear in the urine. Bilirubin in the urine (bilirubinuria) is usually the result of an increase in serum concentration of conjugated bilirubin and indicates an underlying pathological disorder.

Enzymes

The enzymes measured in routine LFTs are listed in Table 6.1. Enzyme concentrations in the serum of healthy individuals are normally low. When cells are damaged, increased amounts of enzymes are detected as the intracellular contents are released into the blood.

It is important to remember that the assay of ‘serum enzymes’ is a measurement of catalytic activity and not actual enzyme concentration and that activity can vary depending on assay conditions. Consequently, the reference range may vary widely between laboratories.

While the measurement of enzymes may be very specific, the enzymes themselves may not be specific to a particular tissue or cell. Many enzymes arise in more than one tissue and an increase in the serum activity of one enzyme can represent damage to any one of the tissues which contain the enzymes. In practice, this problem may be clarified because some tissues contain two or more enzymes in different proportions which are released on damage. For example, alanine and aspartate transaminase both occur in cardiac muscle and liver cells, but their site of origin can often be differentiated, because there is more alanine transaminase in the liver than in the heart. In those situations where it is not possible to look at the relative ratio of enzymes, it is sometimes possible to differentiate the same enzyme from different tissues. Such enzymes have the same catalytic activity but differ in some other measurable property, and are referred to as isoenzymes.

The measured activity of an enzyme will be dependent upon the time it is sampled relative to its time of release from the cell. If a sample is drawn too early after a particular insult to a tissue there may be no detectable increase in enzyme activity. If it is drawn too late, the enzyme may have been cleared from the blood.

Alkaline phosphatase

Alkaline phosphatase is an enzyme which transports metabolites across cell membranes. Alkaline phosphatases are found in the canalicular plasma membrane of hepatocytes, in bone where they reflect bone building or osteoblastic activity, and in the intestinal wall and placenta, kidneys and leucocytes. Each site of origin produces a specific isoenzyme of alkaline phosphatase, which can be electrophoretically separated if concentrations are sufficiently high. Hepatic alkaline phosphatase is present on the surface of bile duct epithelia.

Disorders of the liver which can elevate alkaline phosphatase include intra- or extra-hepatic cholestasis, space-occupying lesions, for example, tumour or abscess, and hepatitis. Drug-induced liver injury, for example, by ACE inhibitors or oestrogens, may present with a cholestatic pattern, that is, a preferential increase in alkaline phosphatase.

Physiological increases in serum alkaline phosphatase activity also occur in pregnancy due to release of the placental isoenzyme and during periods of growth in children and adolescents when the bone isoenzyme is released.

Pathological increases in serum alkaline phosphatase of bone origin may arise in disorders such as osteomalacia and rickets, Paget’s disease of bone, bone tumours, renal bone disease, osteomyelitis and healing fractures. Alkaline phosphatase is also raised as part of the acute-phase response, for example, intestinal alkaline phosphatase may be raised in active inflammatory bowel disease. If in doubt, the origin of the enzyme can be indicated by assessment of γ-glutamyl transpeptidase (see next section) or electrophoresis to separate alkaline phosphatase isoenzymes.

Cardiac markers

Troponins

Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are regulatory proteins that control the calcium-mediated interaction between actin and myosin in cardiac muscle. They are the preferred biomarker for myocardial necrosis as they have near absolute myocardial tissue specificity as well as high clinical sensitivity. The major international cardiac societies have introduced an international definition and classification for myocardial infarction which depends on the detection of a rise and/or fall (≥20%) of troponin with at least one value above the 99th percentile of the upper reference limit (URL) plus at least one of the following: (i) symptoms of ischaemia, or (ii) ECG evidence or imaging evidence of ischaemia. Sampling of cTn at two time points, usually admission and 12 h from worst pain, is usually needed, although if it is entirely clear that there has been a myocardial infarction, particularly in a late presentation, a second sample may not be needed. They contribute significantly to stratification of individuals with acute coronary syndromes, either alone or in combination with admission ECG or a predischarge exercise stress test. The decision as to whether to monitor cTnI or cTnT in a given laboratory is a balance between cost, availability of automated instrumentation and assay performance in which there is not yet standardisation between laboratories. Cardiac troponins offer extremely high tissue specificity and sensitivity but do not discriminate between ischaemic and non-ischaemic mechanisms of myocardial injury, such as myocarditis, cardiac surgery and sepsis. New, more sensitive assays are being developed, although studies will be required to define the clinical significance of minor releases of cTn and its relation to cardiac tissue viability.

Creatine kinase (CK)

CK is an enzyme which is present in relatively high concentrations in heart muscle, skeletal muscle and in brain in addition to being present in smooth muscle and other tissues. Levels are markedly increased following shock and circulatory failure, myocardial infarction and muscular dystrophies. Less marked increases have been reported following muscle injury, surgery, physical exercise, muscle cramp, an epileptic fit, intramuscular injection and hypothyroidism. The most important adverse effects associated with statins are myopathy and an increase in hepatic transaminases, both of which occur infrequently. Statin-associated myopathy represents a broad clinical spectrum of disorders, from mild muscle aches to severe pain and restriction in mobility, with grossly elevated CK levels. In rhabdomyolysis, a potentially life-threatening syndrome resulting from the breakdown of skeletal muscle fibres as a result of ischaemic crush injury, for example, large quantities of CK are measurable in the blood with the level of CK in the blood predicting the developments of acute renal failure. Medications and toxic substances that increase the risk of rhabdomyolysis are shown in Table 6.3.

Table 6.3 Medications and toxic substances that increase the risk of rhabdomyolysis

Direct myotoxicity Indirect muscle damage
HMG-CoA reductase inhibitors, especially in combination with fibrate-derived lipid-lowering agents such as niacin (nicotinic acid) Alcohol
Central nervous system depressants
Cocaine
Ciclosporin Amphetamine
Itraconazole Ecstasy (MDMA)
Erythromycin LSD
Colchicine
Zidovudine
Neuromuscular blocking agents
Corticosteroids  

HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; LSD, lysergic acid diethylamide; MDMA, methylene dioxymethamphetamine.

CK has two protein subunits, M and B, which combine to form three isoenzymes, BB, MM and MB. BB is found in high concentrations in the brain, thyroid and some smooth muscle tissue. Little of this enzyme is present in the serum, even following damage to the brain. The enzyme found in serum of normal subjects is the MM isoenzyme which originates from skeletal muscle.

Cardiac tissue contains more of the MB isoenzyme than skeletal muscle. Following a myocardial infarction there is a characteristic increase in serum CK activity. Although measurement of activity of the MB isoenzyme was used in the past to detect myocardial damage, cardiac troponin measurement is now the preferred biomarker.

Tumour markers

Tumour markers are defined as a qualitative or quantitative alteration or deviation from normal of a molecule, substance or process that can be detected by some type of assay above and beyond routine clinical and pathological evaluation. They may be detected within malignant cells, surrounding stroma or metastases, or as soluble products in blood, secretions or excretions. In order to be useful clinically, the precise use of the marker in altering clinical management should have been defined by data based on a reliable assay, and a validated clinical outcome trial.

Whilst only a few markers contribute to the diagnosis of cancer, serial measurements can be useful in assessing the presence of residual disease and response to treatment. A detailed discussion of each marker, which include prostatic-specific antigen, human chorionic gonadotropin, α-fetoprotein, carcinoembryonic antigen, cancer antigen (CA125 and CA19) is outside the scope of this chapter. Updated National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumour markers in the clinic were published in 2008 to encourage their optimal use. Use in predicting response to therapy and, therefore, targeting therapy is increasingly used: for breast cancer, oestrogen and progesterone receptors are mandatory for predicting response to hormone therapy, and human epidermal growth factor receptor-2 (HER2) measurement is mandatory for predicting response to trastuzumab.

Prostatic specific antigen (PSA) is a serine protease produced by normal and malignant prostatic epithelium and secreted into seminal fluid. Only minor amounts leak into the circulation from the normal prostate, but the release is increased in prostatic disease. It is not recommended for prostate cancer screening but is useful for the detection of recurrence and response to therapy. Free PSA measurement can improve distinguishing of malignant from benign prostatic disease when total PSA is <10 μcg/L, although results for free PSA differ between commercially available assay methods and require harmonisation.

Haematology data

The haematology profile is an important part of the investigation of many patients and not just those with primary haematological disease.

Typical measurements reported in a haematology screen, with their normal values, are shown in Table 6.4, whilst a list of the common descriptive terms used in haematology is presented in Table 6.5.

Table 6.5 Descriptive terms in common use in haematology

Anisocytosis Abnormal variation in cell size (usually refers to RBCs), for example, red cells in iron deficiency anaemia
Agranulocytosis Lack of granulocytes (principally neutrophils)
Aplastic Depression of synthesis of all cell types in bone marrow (as in aplastic anaemia)
Basophilia Increased number of basophils
Hypochromic MCHC low, red cells appear pale microscopically
Leucocytosis Increased white cell count
Leucopenia Reduced white cell count
Macrocytic Large cells
Microcytic Small cells
Neutropenia Reduced neutrophil count
Neutrophilia Increased neutrophil count
Normochromic MCHC normal; red cells appear normally pigmented
Pancytopenia Decreased number of all cell types: it is synonymous with aplastic anaemia
Poikilocytosis Abnormal variation in cell shape, for example, some red cells appear pear shaped in macrocytic anaemias
Thrombocytopenia Lack of platelets

White blood cell (WBC) count

White cells (leucocytes) are of two types: the granulocytes and the agranular cells. They are made up of various types of cells (Fig. 6.4) with different functions and it is logical to consider them separately. A haematology profile often reports a total white cell count and a differential count, the latter separating the composition of white cells into the various types.

Other blood tests

Coagulation

Coagulation is the process by which a platelet and fibrin plug is formed to seal a site of injury or rupture in a blood vessel. The current model of a ‘coagulation network’ differs from the previous popular cascade scheme. It proposes that blood coagulation is localised on the surfaces of activated cells in three overlapping steps: initiation, amplification and propagation. Coagulation is initiated when a tissue factor (TF) bearing cell is exposed to blood flow, following either damage of endothelium such as by perforation of a vessel wall or activation by chemicals, cytokines or the inflammatory process. The formation of a clot then involves a complex interaction between platelets and factor VIII bound to von Willebrand factor which leave the vascular space and adhere to collagen and other matrix components at the site of injury. The coagulation process is amplified when enough thrombin is generated on or near the TF bearing cells to trigger full activation of platelets and coagulation co-factors on the platelet surface. It ends with the generation of sufficient thrombin, to clot fibrinogen. To prevent inappropriate propagation of the thrombus, the process is controlled by naturally occurring anticoagulants and the fibrinolytic system, the final effector of which is plasmin which cleaves fibrin into soluble degradation products. The interaction between TF and factor VII is the most important in the initiation of coagulation and many of the coagulation reactions occur on the surface of cells (particularly platelets). The cellular model of normal haemostasis is shown in Fig. 6.5. Despite the complexity of this model, the basic coagulation tests can still be interpreted in relation to the ‘intrinsic’, ‘extrinsic’, and ‘final common pathway’ components of the traditional and previously held cascade (Fig. 6.6). The extrinsic pathway can be considered to consist of the factor VIIa/TF complex working with the factor Xa/Va complex and the intrinsic pathway to consist of factor XIa working with the complexes of factors VIIIa/IXa and factors Xa/Va. The extrinsic pathway operates on the TF bearing cell to initiate and amplify coagulation with the intrinsic pathway operating on the activated platelet surface to produce the burst of thrombin to form and stabilise the fibrin clot.

Monitoring anticoagulant therapy

The blood tests for the adequacy of the extrinsic pathway, prothombin time (PT) and the intrinsic pathway, activated partial thromboplastin time (aPTT) do not reflect the complexity of haemostasis in vivo, or the risk of bleeding. This requires interpretation of the result in the clinical context of surgical or accidental trauma or medical illness.

Iron, transferrin and iron binding

Iron is necessary for the functioning of all mammalian cells, but is particularly important in cells producing haemoglobin and myoglobin. Iron circulating in the serum is bound to transferrin. It leaves the serum pool and enters the bone marrow where it becomes incorporated into haemoglobin in developing red cells. Serum iron levels are extremely labile and fluctuate throughout the day and, therefore, provide little useful information about iron status.

Transferrin, a simple polypeptide chain with two iron binding sites, is the plasma iron binding protein which facilitates its delivery to cells bearing transferrin receptors. Measurement of total iron binding capacity (TIBC), from which the percentage of transferrin saturation with iron may be calculated, gives more information. Saturation of 16% or lower is usually taken to indicate an iron deficiency, as is a raised TIBC of greater than 70 μmol/L.

Ferritin is an iron storage protein found in cell cytosol. It acts as a depot, accepting excess iron and allowing for mobilisation of iron when needed. Serum ferritin measurement is the test of choice in patients suspected of having iron deficiency anaemia.

In normal individuals, the serum ferritin concentration is directly related to the available storage iron in the body. The serum ferritin level falls below the normal range in iron deficiency anaemia, and its measurement can provide a useful monitor for repletion of iron stores after iron therapy. Ferritin is an acute-phase protein and levels may be normal or high in the anaemia of chronic disease, such as occurs in rheumatoid arthritis or chronic renal disease.

Iron balance is regulated by hepcidin, a circulating peptide hormone, which aims to provide iron as needed, whilst avoiding excess iron promoting formation of toxic oxygen radicals.

Iron overload causes high concentrations of serum ferritin, as can liver disease and some forms of cancer. Genetic iron overload results from mutations in molecules which regulate hepcidin production or activity.

Vitamin B12 and folate

In the haematology literature, B12 refers not only to cyanocobalamin but also to several other cobalamins with identical nutritional properties. Folic acid, which can designate a specific compound, pteroylgutamic acid, is also more commonly used as a general term for the folates. Deficiency of cobalamin can result both in anaemia, usually macrocytic, and neurological disease, including neuropathies, dementia and psychosis. Folate deficiency produces anaemia, macrocytosis, depression, dementia and neural tube defects.

Liver disease tends to increase B12 levels, and they may be reduced in folate deficient patients: malabsorption of B12 may result from long-term ingestion of antacids such as proton-pump inhibitors or H2-receptor antagonists or biguanides (metformin). Serum folate levels tend to increase in B12 deficiency, and alcohol can reduce levels. RBC folate is a better measure of folate tissue stores.

Current assays analyse total B12 concentration, only a small percentage of which is metabolically active. Varying test sensitivities and specificities result from the lack of a precise ‘gold standard’ for the diagnosis of cobalamin deficiency. In the future, new assays for the active component which is carried on holotranscobalamin may be of greater relevance if their clinical usefulness can be established.

Case studies

Case 6.1

Mr F is a 70-year-old man who presents with diffuse pains in his arms and legs. He is Asian, from Pakistan, and has been in England for 50 years.

He has the following biochemical test results:

Alkaline phosphatase 436 U/L
Total calcium 2.27 mmol/L
Ionised calcium 1.10 mmol/L
Phosphate 0.97 mmol/L
Vitamin D 6 nmol/L
Parathyroid hormone 434 ng/L
Urea 4.6 mmol/L
Creatinine 63 μmol/L